X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (18551) 18551
Publication (1848) 1848
Book Review (249) 249
Book / eBook (156) 156
Book Chapter (12) 12
Newsletter (10) 10
Conference Proceeding (9) 9
Dissertation (8) 8
Newspaper Article (6) 6
Paper (5) 5
Presentation (2) 2
Data Set (1) 1
Magazine Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (17127) 17127
oncology (10940) 10940
female (10585) 10585
index medicus (10488) 10488
antineoplastic combined chemotherapy protocols - therapeutic use (8476) 8476
male (8342) 8342
middle aged (7482) 7482
aged (6770) 6770
chemotherapy (6697) 6697
cancer (6513) 6513
adult (6277) 6277
treatment outcome (4386) 4386
animals (4177) 4177
pharmacology & pharmacy (3927) 3927
antineoplastic combined chemotherapy protocols - adverse effects (3911) 3911
antineoplastic agents - therapeutic use (3183) 3183
care and treatment (2950) 2950
medicine & public health (2909) 2909
antineoplastic combined chemotherapy protocols - administration & dosage (2891) 2891
pharmacokinetics (2493) 2493
neoplasms - drug therapy (2438) 2438
research (2350) 2350
dose-response relationship, drug (2341) 2341
antineoplastic agents (2297) 2297
mice (2203) 2203
antineoplastic agents - administration & dosage (2198) 2198
therapy (2158) 2158
cell line, tumor (2144) 2144
hematology (2141) 2141
drug administration schedule (2095) 2095
antimitotic agents (2006) 2006
drug therapy (1951) 1951
analysis (1925) 1925
aged, 80 and over (1909) 1909
tumors (1902) 1902
antineoplastic agents - pharmacology (1882) 1882
cisplatin (1874) 1874
breast neoplasms - drug therapy (1844) 1844
antineoplastic combined chemotherapy protocols - pharmacokinetics (1828) 1828
pharmacology/toxicology (1669) 1669
lung neoplasms - drug therapy (1582) 1582
health aspects (1571) 1571
disease-free survival (1570) 1570
cisplatin - administration & dosage (1546) 1546
antineoplastic agents - adverse effects (1538) 1538
clinical trials (1530) 1530
paclitaxel (1493) 1493
breast cancer (1486) 1486
fluorouracil - administration & dosage (1486) 1486
combined modality therapy (1481) 1481
prognosis (1481) 1481
trial (1472) 1472
toxicity (1469) 1469
apoptosis (1443) 1443
metastasis (1441) 1441
cancer research (1430) 1430
adolescent (1419) 1419
neoplasm staging (1342) 1342
deoxycytidine - analogs & derivatives (1337) 1337
combination (1333) 1333
antineoplastic agents - pharmacokinetics (1298) 1298
survival rate (1294) 1294
article (1291) 1291
antineoplastic combined chemotherapy protocols - pharmacology (1290) 1290
paclitaxel - administration & dosage (1265) 1265
survival (1257) 1257
survival analysis (1209) 1209
doxorubicin (1187) 1187
carcinoma (1180) 1180
doxorubicin - administration & dosage (1172) 1172
cancer therapies (1164) 1164
child (1144) 1144
maximum tolerated dose (1104) 1104
hematology, oncology and palliative medicine (1096) 1096
clinical trials as topic (1092) 1092
dosage and administration (1085) 1085
colorectal neoplasms - drug therapy (1084) 1084
carcinoma, non-small-cell lung - drug therapy (1083) 1083
drug synergism (1083) 1083
apoptosis - drug effects (1074) 1074
deoxycytidine - administration & dosage (1067) 1067
phase-ii (1066) 1066
neoplasm metastasis (1036) 1036
solid tumors (1035) 1035
fluorouracil (1013) 1013
docetaxel (1004) 1004
camptothecin - analogs & derivatives (1000) 1000
5-fluorouracil (997) 997
breast neoplasms - pathology (995) 995
pharmacology (989) 989
infusions, intravenous (988) 988
phase-ii trial (988) 988
cell lung-cancer (978) 978
retrospective studies (957) 957
breast-cancer (955) 955
expression (955) 955
colorectal cancer (950) 950
drugs (935) 935
gemcitabine (933) 933
xenograft model antitumor assays (924) 924
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (120) 120
Collection Dvlpm't (Acquisitions) - Vendor file (10) 10
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (5) 5
Online Resources - Online (3) 3
Gerstein Science - Circulation Desk (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Credit Valley Hospital - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18439) 18439
Japanese (174) 174
French (37) 37
German (29) 29
Spanish (19) 19
Chinese (14) 14
Hungarian (5) 5
Italian (5) 5
Russian (4) 4
Polish (3) 3
Dutch (2) 2
Portuguese (2) 2
Swedish (2) 2
Danish (1) 1
Hebrew (1) 1
Manx (1) 1
Norwegian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 27, pp. 3327 - 3334
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
The combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with metastatic melanoma produced a significantly higher response... 
CELL LUNG-CANCER | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | EFFICACY | PATHWAY | SAFETY | KINASE | RESISTANCE | DOSE-ESCALATION TRIAL | RAF INHIBITORS | IMPROVED SURVIVAL | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
Science, ISSN 0036-8075, 5/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | NANOPARTICLES | INTEGRINS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | IN-VIVO | DOXORUBICIN | PHAGE DISPLAY | VASCULAR-PERMEABILITY FACTOR | CELL | ENDOTHELIAL GROWTH-FACTOR | DELIVERY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 11/2016, Volume 13, Issue 11, pp. 659 - 673
Metronomic chemotherapy describes the close, regular administration of chemotherapy drugs at less-toxic doses over prolonged periods of time. In 2015, the... 
IN-VITRO | ANTIANGIOGENIC ACTIVITY | ONCOLOGY | RANDOMIZED PHASE-II | BREAST-CANCER PATIENTS | ANTITUMOR INNATE IMMUNITY | ORAL TOPOTECAN | CYCLOPHOSPHAMIDE TREATMENT | ANTICANCER DRUGS | CLINICAL PHARMACOKINETICS | DOSE CHEMOTHERAPY | Angiogenesis Inhibitors - immunology | Pyrimidines - immunology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Administration, Metronomic | Breast Neoplasms - immunology | Alkylating Agents - immunology | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Angiogenesis Inhibitors - administration & dosage | Clinical Trials, Phase III as Topic | Colorectal Neoplasms - drug therapy | Tubulin Modulators - administration & dosage | Alkylating Agents - pharmacokinetics | Camptothecin - administration & dosage | Female | Camptothecin - immunology | Camptothecin - pharmacokinetics | Pyrimidines - administration & dosage | Tubulin Modulators - pharmacokinetics | Alkylating Agents - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - immunology | Breast Neoplasms - drug therapy | Forecasting | Randomized Controlled Trials as Topic | Immunity, Cellular - immunology | Colorectal Neoplasms - immunology | Tubulin Modulators - immunology | Pyrimidines - pharmacokinetics | Chemotherapy | Care and treatment | Patient outcomes | Forecasts and trends | Pharmacokinetics | Observations | Methods | Cancer | Index Medicus
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination... 
trametinib | melanoma | durable outcomes | BRAF | metastatic | dabrafenib | MULTICENTER | OPEN-LABEL | COMBINATION | TRIAL | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | POOLED ANALYSIS | NIVOLUMAB | IPILIMUMAB | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Pyridones - administration & dosage | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Protein Kinase Inhibitors - pharmacokinetics | Skin Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Melanoma - secondary | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Original
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 6/2013, Volume 71, Issue 6, pp. 1521 - 1530
A growing number of preclinical studies have demonstrated that curcumin could be a promising anticancer drug; however, poor bioavailability has been the major... 
Medicine & Public Health | Gemcitabine | Pancreatic cancer | Oncology | Cancer Research | Curcumin | Theracurmin | Bioavailability | Pharmacology/Toxicology | APOPTOSIS | Theracurmin (R) | CLINICAL-TRIAL | FACTOR-KAPPA-B | PROLIFERATION | ENCAPSULATED CURCUMIN | ADVANCED PANCREATIC-CANCER | THERAPY | ONCOLOGY | SUPPRESSES GROWTH | CHEMOPREVENTIVE AGENT | PHARMACOLOGY & PHARMACY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Pancreatic Neoplasms - metabolism | Antineoplastic Combined Chemotherapy Protocols - chemistry | Curcumin - chemistry | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Biological Availability | Male | Biliary Tract Neoplasms - mortality | Curcumin - administration & dosage | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Biliary Tract Neoplasms - metabolism | Aged, 80 and over | Drug Compounding | Female | Pancreatic Neoplasms - mortality | Biliary Tract Neoplasms - drug therapy | Cytokines - immunology | NF-kappa B - antagonists & inhibitors | Drug Administration Schedule | Drug Stability | Curcumin - pharmacokinetics | Solubility | Curcumin - adverse effects | Disease-Free Survival | Maximum Tolerated Dose | Quality of Life | Aged | Cytokines - antagonists & inhibitors | Medical colleges | Cancer patients | Care and treatment | Chemotherapy | Safety and security measures | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Journal Article
Blood, ISSN 0006-4971, 06/2017, Volume 129, Issue 25, pp. 3294 - 3303
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2011, Volume 29, Issue 3, pp. 489 - 498
Journal Article